Human Claudin-18.2 Full Length Protein (VLP)
分子别名（Synonym）
Claudin-18.2, CLDN18, Claudin-18
表达区间及表达系统（Source）
Human Claudin-18.2 Full Length Protein-VLP (CL2-H52P7) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Val 261 (Accession # P56856-2 ).
Predicted N-terminus: Met 1
蛋白结构（Molecular Characterization）
Virus-like particles(VLPs) are formed by self-assembly of capsid proteins from viruses. Membrane Proteins can be constituted in-situ with VLPs produced from HEK293 cell cultures. These VLPs concentrate conformationally intact membrane proteins directly on the cell surface and produce soluble, high-concentration proteins perfect for immunization and antibody screening.
The VLPs provide the display of properly folded membrane proteins in their native cellular membrane in a compact size of 100~300 nm diameter (similar to the size of most viruses) making it optimal targets for dendritic cells in vivo and surface attachment for phage display.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method / rFC method.
纯度（Purity）
>95% as determined by SEC-HPLC.
制剂（Formulation）
The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).
Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
运输（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存储（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 12 months under sterile conditions.
背景介绍
紧密连接蛋白(Claudins, CLDNs)是形成紧密连接、维持上皮细胞和内皮细胞极性的蛋白质家族。CLDN18特异性表达于胃和肺组织。通过可变剪接产生的两种CLDN18转录异构体中，CLDN18.2是决定肿瘤状态下胃表型的高度选择性胃谱系标志物，而CLDN18.1具有肺组织特异性。CLDN18.2作为高度选择性胃谱系抗原，仅表达于短寿命分化的胃上皮细胞，其抗体药物可及性有限<sup>14,15</sup>。该抗原在恶性转化过程中持续存在，因此常见于人类胃癌细胞表面。
关键字： Claudin-18.2;Claudin-18.2蛋白;Claudin-18.2重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。